The East Windsor, Mercer County-based pharmaceutical company said that, as of June 30, stockholder equity was $1.7 million, below Nasdaq's minimum $2.5 million.
"In our response to Nasdaq, we will request that Nasdaq take note of our continuing restructuring and cost-containment program begun in December 2008 as well as potential revenue opportunities from the licensing of our products under development," said Mark Westgate, NexMed's chief financial officer.
Acceptance of the plan would give the company a 105-day extension.
The company is still on notice over meeting the minimum $1 bid, but a temporary suspension of this rule has extended the company's deadline until January. Company shares have traded between 5 cents and $1.54 in the last 52 weeks, and last closed above $1 on Aug. 26.
Shares were priced at 17 cents, down 2 cents, at midafternoon today.
The company's pipeline includes a treatment for onychomycosis (a fungus infection of the toenails), erectile dysfunction, female sexual arousal disorder, and psoriasis. -- Roslyn Rudolph
To see more of The Philadelphia Inquirer, or to subscribe to the newspaper, go to http://www.philly.com/inquirer. Copyright (c) 2009, The Philadelphia Inquirer Distributed by McClatchy-Tribune Information Services. For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index